U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07851220) titled 'A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy' on Sept. 25.
Brief Summary: The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Glomerulonephritis, Membranous
Intervention:
DRUG: Inebilizumab
Inebilizumab will be administered via IV infusion.
DRUG: Tacrolimus
Tacrolimus will be administered orally
Recruitment Status: RECRUITING
Sponsor: Amgen
Disclaimer: Curated by HT Syndication....